Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy?

[1]  P. Wiffen,et al.  WITHDRAWN: Gabapentin for acute and chronic pain. , 2011, The Cochrane database of systematic reviews.

[2]  Ian M. Fowler,et al.  Profound pain reduction after induction of memantine treatment in two patients with severe phantom limb pain. , 2008, Anesthesia and analgesia.

[3]  A. May.  Chronic pain may change the structure of the brain , 2008, PAIN®.

[4]  R. Barkin,et al.  Dilemmas in chronic/persistent pain management. , 2008, American journal of therapeutics.

[5]  K. Ha,et al.  Pregabalin as a neuroprotector after spinal cord injury in rats , 2008, European Spine Journal.

[6]  Patrick E. Rothwell,et al.  Effects of the NMDA receptor antagonist memantine on the expression and development of acute opiate dependence as assessed by withdrawal-potentiated startle and hyperalgesia , 2008, Psychopharmacology.

[7]  N. Gajraj.  Pregabalin: Its Pharmacology and Use in Pain Management , 2007, Anesthesia and analgesia.

[8]  R. Luerding,et al.  Striatal grey matter increase in patients suffering from fibromyalgia – A voxel-based morphometry study , 2007, PAIN.

[9]  Daniel J Clauw,et al.  Decreased Central μ-Opioid Receptor Availability in Fibromyalgia , 2007, The Journal of Neuroscience.

[10]  P. Calabresi,et al.  Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. , 2007, The journal of pain : official journal of the American Pain Society.

[11]  David A Seminowicz,et al.  Accelerated Brain Gray Matter Loss in Fibromyalgia Patients: Premature Aging of the Brain? , 2007, The Journal of Neuroscience.

[12]  P. Keck,et al.  Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. , 2007, Arthritis and rheumatism.

[13]  N. Birbaumer,et al.  Memantine Treatment of Complex Regional Pain Syndrome: A Preliminary Report of Six Cases , 2007, The Clinical journal of pain.

[14]  S. DeMaria,et al.  N-Methyl-D-Aspartate Receptor-Mediated Chronic Pain: New Approaches to Fibromyalgia Syndrome Etiology and Therapy , 2007 .

[15]  Yu-Qing Cao,et al.  Voltage-gated calcium channels and pain , 2006, Pain.

[16]  M. Meeus,et al.  Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome , 2006, Clinical Rheumatology.

[17]  Bogdan Draganski,et al.  Affective components and intensity of pain correlate with structural differences in gray matter in chronic back pain patients , 2006, Pain.

[18]  A. Apkarian,et al.  Shared mechanisms between chronic pain and neurodegenerative disease , 2006 .

[19]  P. Sarzi-Puttini,et al.  Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome , 2006, Arthritis research & therapy.

[20]  D. Clauw,et al.  Therapy Insight: fibromyalgia—a different type of pain needing a different type of treatment , 2006, Nature Clinical Practice Rheumatology.

[21]  S. Lipton,et al.  The chemical biology of clinically tolerated NMDA receptor antagonists , 2006, Journal of neurochemistry.

[22]  S. Ozgoçmen,et al.  Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide , 2006, Rheumatology International.

[23]  R. Staud.  Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome , 2006, Arthritis research & therapy.

[24]  S. Seino,et al.  Enhanced neuronal damage after ischemic insults in mice lacking Kir6.2-containing ATP-sensitive K+ channels. , 2006, Journal of neurophysiology.

[25]  Sheng-Nan Wu,et al.  The Opening Effect of Pregabalin on ATP‐Sensitive Potassium Channels in Differentiated Hippocampal Neuron–derived H19‐7 Cells , 2006, Epilepsia.

[26]  I. Moon,et al.  Increased expression of N-methyl-D-aspartate receptor subunit 2D in the skin of patients with fibromyalgia. , 2006, The Journal of rheumatology.

[27]  Manuela G. López,et al.  Involvement of PKA, MAPK/ERK and CaMKII, but not PKC in the acute antidepressant-like effect of memantine in mice , 2006, Neuroscience Letters.

[28]  S. Lipton.  Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond , 2006, Nature Reviews Drug Discovery.

[29]  A Straube,et al.  Gray matter decrease in patients with chronic tension type headache , 2005, Neurology.

[30]  A. Melemeni,et al.  Multimodal Analgesia with Gabapentin and Local Anesthetics Prevents Acute and Chronic Pain After Breast Surgery for Cancer , 2005, Anesthesia and analgesia.

[31]  Ivan Toni,et al.  Gray matter volume reduction in the chronic fatigue syndrome , 2005, NeuroImage.

[32]  E. Whalen,et al.  Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens , 2005, Pain.

[33]  C. Vierck,et al.  Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. , 2005, The journal of pain : official journal of the American Pain Society.

[34]  M. Rowbotham,et al.  Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[35]  L. Tamer,et al.  Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? , 2005, Rheumatology International.

[36]  G. Oster,et al.  Analgesic outcomes in patients with painful diabetic neuropathy or post-herpetic neuralgia receiving pregabalin versus gabapentin , 2005 .

[37]  C. Summerfield,et al.  Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. , 2005, Archives of neurology.

[38]  Alan C. Evans,et al.  Cerebral atrophy and its relation to cognitive impairment in Parkinson disease , 2005, Neurology.

[39]  D. Clauw,et al.  Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain , 2004, BMC musculoskeletal disorders.

[40]  A. Apkarian,et al.  Chronic Back Pain Is Associated with Decreased Prefrontal and Thalamic Gray Matter Density , 2004, The Journal of Neuroscience.

[41]  Norihiro Sadato,et al.  Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome , 2004, BMC neurology.

[42]  R. Ji,et al.  Cell Signaling and the Genesis of Neuropathic Pain , 2004, Science's STKE.

[43]  A. Stöffler,et al.  Memantine hydrochloride: pharmacological and clinical profile. , 2004, Drugs of today.

[44]  M. Daly,et al.  Segmental phylogenetic relationships of inbred mouse strains revealed by fine-scale analysis of sequence variation across 4.6 mb of mouse genome. , 2004, Genome research.

[45]  J. Rosenstock,et al.  Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial , 2004, Pain.

[46]  M. Versavel,et al.  Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial , 2004, Pain.

[47]  Z. Bajwa,et al.  Principles and Practice of Pain Medicine , 2004 .

[48]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[49]  S. Schulz,et al.  Heterodimerization of Substance P and μ-Opioid Receptors Regulates Receptor Trafficking and Resensitization* , 2003, Journal of Biological Chemistry.

[50]  C. Bountra,et al.  Pain : Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery , 2003 .

[51]  Rachelle Doody,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[52]  M. Fredrikson,et al.  Retrosplenial cortical activation in the fibromyalgia syndrome , 2003, Neuroreport.

[53]  S. Ackerman,et al.  Oxidative stress, cell cycle, and neurodegeneration. , 2003, The Journal of clinical investigation.

[54]  Kiralee M. Hayashi,et al.  Dynamics of Gray Matter Loss in Alzheimer's Disease , 2003, The Journal of Neuroscience.

[55]  A. Fassoulaki,et al.  The Analgesic Effect of Gabapentin and Mexiletine After Breast Surgery for Cancer , 2002, Anesthesia and analgesia.

[56]  R. Staud.  Evidence of involvement of central neural mechanisms in generating fibromyalgia pain , 2002, Current rheumatology reports.

[57]  L. Rowland,et al.  Reduced hippocampal volume and total white matter volume in posttraumatic stress disorder , 2002, Biological Psychiatry.

[58]  E. T. Bullmore,et al.  Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS , 2001, Neurology.

[59]  A. Unruh,et al.  Pain: A Textbook for Therapists , 2001 .

[60]  Jennifer M. Glass,et al.  Cognitive function in fibromyalgia patients. , 2001, Arthritis and rheumatism.

[61]  Q. Hogan,et al.  Gabapentin Decreases Membrane Calcium Currents in Injured as Well as in Control Mammalian Primary Afferent Neurons , 2001, Regional Anesthesia & Pain Medicine.

[62]  Jennifer M. Glass,et al.  Cognitive dysfunction in fibromyalgia , 2001, Current rheumatology reports.

[63]  K. Pile,et al.  Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. , 2000, Arthritis and rheumatism.

[64]  L. Tanum.  [Functional somatic syndromes]. , 2000, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[65]  T. Jensen,et al.  Memantine (a N-Methyl-d-Aspartate Receptor Antagonist) in the Treatment of Neuropathic Pain After Amputation or Surgery: A Randomized, Double-Blinded, Cross-Over Study , 2000, Anesthesia and analgesia.

[66]  I. Russell,et al.  Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways , 2000, Pain.

[67]  A. Weinbroum,et al.  The role of dextromethorphan in pain control , 2000, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[68]  L. Arendt-Nielsen,et al.  Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients , 2000, Pain.

[69]  J. Macdonald,et al.  Distinct Roles of Synaptic and Extrasynaptic NMDA Receptors in Excitotoxicity , 2000, The Journal of Neuroscience.

[70]  D. Moore-Nichols,et al.  Calcium Influx Through NMDA Receptors, Chronic Receptor Inhibition by Ethanol and 2‐Amino‐5‐Phosphonopentanoic Acid, and Receptor Protein Expression , 1999, Journal of neurochemistry.

[71]  P. Tugwell,et al.  The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. , 1990, Arthritis and rheumatism.

[72]  M. Siddiqui,et al.  Pregabalin , 2012, Drugs.

[73]  B. Reisberg,et al.  A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. , 2006, Archives of neurology.

[74]  Lo Sj,et al.  Review of NMDA antagonist-induced neurotoxicity and implications for clinical development. , 2004 .

[75]  D. Weigent,et al.  Abnormal Regional Cerebral Blood Flow in the Caudate Nucleus Among Fibromyalgia Patients and Non-Patients Is Associated with Insidious Symptom Onset , 1999 .